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Available online 4 October 2016Angiogenesis is important in cancer progression and can be inﬂuenced by tumor-associated myoﬁbroblasts. We
addressed the hypothesis that glucocorticoids indirectly affect angiogenesis by altering the release of pro-angio-
genic factors from colon cancer-derived myoﬁbroblasts.
Our study shows that glucocorticoids reduced prostanoids, urokinase-type plasminogen activator (uPA) and
angiopoietin-like protein-2 (ANGPTL2) levels, but increased angiogenin (ANG) in supernatant from human
CT5.3hTERT colon cancer-derived myoﬁbroblasts. Conditioned medium from solvent- (CMS) and dexametha-
sone (Dex)-treated (CMD) myoﬁbroblasts increased human umbilical vein endothelial cell (HUVEC) prolifera-
tion, but did not affect expression of pro-angiogenic factors or tube-like structure formation (by HUVECs or
human aortic ECs). In a HUVEC scratch assay CMS-induced acceleration of wound healing was blunted by CMD
treatment. Moreover, CMS-induced neovessel growth in mouse aortic rings ex vivo was also blunted using
CMD. The latter effect could be ascribed to both Dex-driven reduction of secreted factors and potential residual
Dex present in CMD (indicated using a dexamethasone-spiked CMS control). A similar control in the scratch
assay, however, revealed that altered levels of factors in the CMD, and not potential residual Dex, were respon-
sible for decreased wound closure.
In conclusion, our results suggest that glucocorticoids indirectly alter endothelial cell function during tumor de-
velopment in vivo.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Angiogenesis, the formation of new blood vessels from an existing
vascular network [1], is essential for embryonic growth. In healthy
adults angiogenesis is restricted to discrete physiological processes
(e.g. the regulation of the reproductive tract, muscle growth) and con-
tributes to wound healing [2]. Excessive or impaired angiogenesis has
also been implicated in disease pathogenesis (e.g. in malignant or in-
ﬂammatory disorders [2]), and is associated with promotion of tumor
growth and metastasis. Consequently, the potential of angiogenesis as.2017.01.003.
ke).
rtment Health Sciences, Odisee
t, Belgium; Ilse.Beck@odisee.be.
Inc. This is an open access article ua therapeutic target (e.g. in cancer [1–3], retinopathy [4] and tissue is-
chemia [5]) has attracted considerable research interest.
Tumors use blood vessels not only as a source of nutrients and oxy-
gen, but also to transport cancer cells to establish a new, metastatic site
[6]. Cancer cells can directlymodulate angiogenesis via secretion of pro-
angiogenic factors, such as vascular endothelial growth factor (VEGF),
angiopoietins, basic ﬁbroblast growth factor (bFGF), interleukins (ILs)
or transforming growth factors (TGFs) [3,7]. Epithelial tumors consist
of cancer cells and a surrounding microenvironment composed of an
extracellular matrix, stromal cells, inﬂammatory cells and endothelial
cells (ECs). All these components play an important role during tumor
development [8]. Cancer-associated ﬁbroblasts (myoﬁbroblasts) are
present at the invasive edge of the tumor and share properties of both
smooth-muscle cells and ﬁbroblasts. Myoﬁbroblasts, which are essen-
tial during wound healing and embryonic development [9], can also in-
ﬂuence tumor progression [10,11] either directly, through paracrine
signaling to cancer cells, or indirectly, by modulation of protease activi-
ty, modulation of extracellular matrix remodeling, and recruitment ofnder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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function and inﬂuence tumor angiogenesis [8,11]. In breast cancer, can-
cer-associated ﬁbroblasts promote vascularization by recruiting endo-
thelial progenitor cells to the tumor via increased release of stromal-
cell derived factor 1 (SDF-1) [12]. Moreover, prostaglandin (PG)E2-
stimulated intestinal sub-epithelial myoﬁbroblasts display an increased
expression of vascular endothelial growth factor (VEGF) andhepatocyte
growth factor/scatter factor (HGF/SF), which promote EC migration
[13].
Glucocorticoids (GCs) are steroidal ligands of the glucocorticoid re-
ceptor (GR), which belongs to the nuclear receptor superfamily. Stimu-
lation of GR regulates many physiological processes, mainly via gene
transactivation or transrepression [14]. Consequently, glucocorticoids
are clinically important as potent anti-inﬂammatory compounds in
treatment of autoimmune diseases [15], and as adjuvants in cancer
therapy [16]. Moreover, GCs provide an effective treatment of infantile
hemangiomas (IHs) [17]. GC-mediated inhibition of angiogenesis is
well-documented [18] and has therapeutic potential in the treatment
of cancer [19,20]. The direct, growth-inhibitory inﬂuence of GCs on vas-
cular smooth muscle cells is well-established [21,22]. Furthermore,
more recent investigations have demonstrated GR-dependent, GC-me-
diated inhibition of tube-like structure formation by ECs in vitro, inde-
pendent of GCs' anti-inﬂammatory actions [23]. GCs can also inhibit
angiogenesis indirectly by suppression of pro-angiogenic factors, such
as VEGF and IL-8, produced by prostate cancer cells [20], and possibly
by extracellular matrix degradation or modiﬁcation of cytokine produc-
tion [24].
We recently reported that GCs regulate myoﬁbroblasts, decreasing
production and secretion of a number of factors linked to cancer pro-
gression and invasion: tenascin C (TNC), TGFβ, HGF/SF [25–27]. These
factors are all known to also affect the angiogenic response through a
number of mechanisms [28–30]. Combined with our data, these studies
suggest that GCs could have the ability to inhibit myoﬁbroblast-induced
stimulation of angiogenesis by altering the composition of the
myoﬁbroblast secretome. Therefore, this investigation addressed the
hypothesis that exposure of colon cancer-derived myoﬁbroblasts to
GCs can reduce secretion of angiogenic factors and thus inhibit their
ability to promote pro-angiogenic changes in ECs.
2. Materials and methods
2.1. Cells and reagents
Human stromal colon cancer-derived myoﬁbroblasts (CT5.3hTERT
cells) were isolated as described [26,31] and cultured (37 °C, 10% CO2)
in Dulbecco's modiﬁed Eagles Medium (DMEM; Life Technologies,
Merelbeke, Belgium) supplemented with 10% fetal calf serum (Greiner
bio-one, Wemmel, Belgium), 100 U/ml penicillin and 0.1 mg/ml strep-
tomycin (Life Technologies). Primary human umbilical vein endothelial
cells (HUVEC; Promocell, Heidelberg, Germany) and human aortic en-
dothelial cells (HAoEC; Promocell) were cultured in Endothelial Cell
Growth Medium-2 (EGM2; Lonza, Wokingham, UK), containing all
manufacturer-supplied supplements (2% FCS, 0.1% VEGF, 0.4% hFGF-2,
0.1% R3-IGF-1, 0.1% hEGF, 0.1% ascorbic acid, 0.1% heparin, 0.1% GA-
100) except hydrocortisone. HUVECs were cultured (37 °C, 5% CO2) on
0.1% gelatin-coated ﬂasks and were studied between passages 2 and 7.
In experiments we used EGM2 containing 2% FCS or 0% FCS, abbreviated
respectively EGM2S+ and EGM2S−.
Dexamethasone (Dex), hydrocortisone (Hcrt), prednisolone (Pred),
ﬂuocinolone acetonide (FA) and the GR antagonist RU38486 (RU)
were purchased from Sigma-Aldrich (Diegem, Belgium). All reagents
were dissolved in ethanol and used at a ﬁnal concentration of 1 μM, ex-
cept RU (2 μM). A selective GR modulator (SEGRM), compound A
(CpdA) was prepared as previously described [32] and used at a ﬁnal
concentration of 10 μM. The total solvent concentration (maximally
0.1%) was consistent in all conditions.2.2. Conditioned medium preparation
Conditionedmedium (CM)was obtained from 10 × 106 CT5.3hTERT
myoﬁbroblasts and prepared as described [26]. Brieﬂy, cells were
washed three times with serum-free DMEM and treated for 48 h with
solvent (ethanol), Dex (1 μM), Hcrt (1 μM), Pred (1 μM), CpdA
(10 μM) or RU (2 μM) in serum-free DMEM. After this incubation CM
was collected, concentrated 10-fold using centrifugal ﬁlter tubes with
a 3 kDa cut-off (Amicon Ultra, Merck Millipore, Darmstadt, Germany),
ﬁlter-sterilized (0.2 μm pore size) and stored (−20 °C) for subsequent
functional and biochemical assays. For functional assays CM from sol-
vent and Dex-treated myoﬁbroblasts (CMS and CMD, respectively)
were diluted with EGM2S+ or EGM2S− or with serum-free DMEM
prior to treatment. Taking into account the concentrating procedure of
CM and further dilution in the functional assays, the maximal ﬁnal con-
centration of Dex in the CMD treatmentwas calculated to be 50 nM. CM
concentrations and dilutions used in particular experiments are listed in
Supplementary Table 1.
2.3. Protein analysis: protein array,Western blot and immunoassay (ELISA)
CM from CT5.3hTERT myoﬁbroblasts treated with Dex or solvent
(CMS and CMD, respectively) were collected after 48 h, 4-fold concen-
trated and subjected to Ray Bio® Biotin Label-based Human Antibody
Array I (Raybiotech, GA, USA, cat no: AAH-BLM-I-2)which allows simul-
taneous analysis of expression levels of 507 human target proteins (in-
cluding cytokines, chemokines, adipokines, growth factors, angiogenic
factors, proteases, soluble receptors and soluble adhesion molecules)
in cell culture supernatants. The assay was performed according to the
manufacturer's instructions with the results visualized using X-Ray
ﬁlms (GE Healthcare, Diegem, Belgium) and the signal evaluated using
ImageJ software [33]. For further analysis, we set the threshold value
for the ratio between relative protein signals in CMS vs. CMDasN1.5. Se-
lected factors analyzed using the protein array are listed in Supplemen-
tary Table 2.
For further validation of the protein array results, CT5.3hTERT
myoﬁbroblasts were incubated for 48 h with steroids (Dex, Hcrt, Pred;
1 μM), CpdA (10 μM), RU (2 μM) or solvent. Conditioned media were
collected, concentrated (10-fold) and protein concentrationswere eval-
uatedusing the Lowrymethod [34]. Sampleswere prepared in SDS sam-
ple buffer (50mMTris pH 6.8; 2% SDS; 10% glycerol; bromophenol blue;
100 mM DTT), loaded (25 μg) onto an SDS-PAGE gel and subjected to
the standard Western blot protocol, as described by Santa Cruz (Santa
Cruz, Heidelberg, Germany). The proteins were probed using the fol-
lowing primary anti-human antibodies: anti-uPA (H-140) (1/500,
Santa Cruz Biotechnology, cat no: sc-14019), anti-ANG I (H-123) (1/
500, Santa Cruz Biotechnology, cat no: sc-9044) and anti-ANGPTL2 (P-
13) (1/500, Santa Cruz Biotechnology, cat no: sc-107143). Results
were visualized using species-speciﬁc HRP-linked secondary antibodies
and reagents: anti-rabbit (1/4000, GEHealthcare, cat no: NA934V), anti-
goat (1/3000, Santa Cruz Biotechnology, cat no: sc-2020), ECL solution
(Thermo Scientiﬁc, Gent, Belgium) and X-Ray ﬁlms (GE Healthcare).
Signal quantiﬁcations were performed using ImageJ software [33].
The internalization and subsequent degradation of the acetylated
low density lipoprotein (Ac-LDL) is a characteristic feature of endothe-
lial cells. In order to evaluate whether the conditioned medium from
myoﬁbroblasts affects the basic endothelial character of HUVECs, we
performed an Ac-LDL uptake assay. Brieﬂy HUVECs were incubated for
24 h in EGM2S+ (control), DMEM, CMS or CMD. DMEM and 10-fold
concentrated CM were diluted 1:1 with EGM2S+. An Ac-LDL assay was
then performed, as described (see Supplementary methods in
Supporting Information).
In order to determine the concentrations of prostanoids in condi-
tioned medium from myoﬁbroblasts and HUVECs, and in HUVEC ly-
sates, we performed immunoassays (ELISAs) for prostaglandin F2α
(PGF2α), prostacyclin (PGI2; by assessing 6-keto-PGF1α) and
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Life Sciences, Antwerp, Belgium, cat no: ADI-900-069, ADI-900-001 and
ADI-900-004, respectively). Absorbance was quantiﬁed on Paradigm
Detection Platform (Beckman Coulter) using SoftMax Pro 6.1 software.
HUVEC lysates were prepared from cells treated with EGM2S+ (con-
trol), CMS or CMD (diluted 1:1 with EGM2S+, giving a ﬁnal 5-fold con-
centration of CM). After 24 h cells were lyzed with TOTEX buffer
(20 mM Hepes/KOH pH 7.9; 0.35 M NaCl; 20% glycerol; 1% NP40;
1 mM MgCl2; 0.5 mM EDTA; 0.1 mM EGTA; 1/100 HALT Protease and
Phosphatase Inhibitor Cocktail, ThermoFisher Scientiﬁc, cat no: 78440)
and the lysates were subjected to immunoassays.
2.4. RNA isolation and RT-qPCR
CT5.3hTERT myoﬁbroblasts were incubated for 48 h with steroids
(Dex, Hcrt, FA, Pred; 1 μM), CpdA (10 μM), RU (2 μM) or solvent (con-
trol). HUVECs were incubated for 24 h with EGM2S+ (control),
DMEM, CMS or CMD. DMEM and CM were diluted 1:1 with EGM2S+,
the ﬁnal CM concentration was 5-fold. To isolate the total RNA from
myoﬁbroblasts we used TRIzol reagent (Life Technologies) and to iso-
late HUVEC RNAwe used an RNeasy Kit (Qiagen, Hilden, Germany), ac-
cording to themanufacturer's instructions. Reverse transcription (RT) of
myoﬁbroblast RNAwas performed using the iScript kit (Bio-Rad, Temse,
Belgium),whilst RT of HUVEC RNAwas performed usingQuantiTect Re-
verse Transcription Kit (Qiagen). The cDNA obtained was subjected to
quantitative PCR (qPCR) using LightCycler 480 SYBR Green I Master re-
agents (Roche Diagnostics, Rotkreuz, Switzerland), according to the
manufacturer's instructions. qPCR reactions were performed in tripli-
cate using the LightCycler 480 system (Roche Diagnostics), with the fol-
lowing conditions: (A) initial denaturation 95 °C, 5min; (B) 45 cycles of
denaturation 95 °C, 15 s, annealing and elongation 60 °C, 45 s. Primer se-
quences are listed in Supplementary Table 3. Speciﬁc signal of the gene
of interest was normalized to the respective geometricmean expression
level of 3 reference genes (GAPDH, PPIB, 36B4).
2.5. Cell viability (MTT) and proliferation (SRB) assays
To test viability HUVECs were seeded in 96-well plates, equilibrated
in EGM2S+ for 24 h and incubated for 24 h with DMEM, CMS or CMD.
DMEM and 10-fold concentrated CM were diluted 1:1 with EGM2S+.
As a negative control HUVECs were treated with 10% Triton X-100
(Sigma-Aldrich) for 1 h (data not shown). Cell viability was assessed
using a classic 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay [35], performed with reagents purchased from
Sigma-Aldrich.
Proliferation was assessed using a sulforhodamine-B (SRB) test, as
described previously [36]. HUVECs seeded in 96-well plates were left
to equilibrate in EGM2S+ for 24 h and then incubated in EGM2S+ or
EGM2S−, DMEM, CMS, CMS + Dex (50 nM) or CMD for 24-72 h.
DMEM and 10-fold concentrated CM were diluted 1:1 with EGM2S+
or EGM2S−. Results were obtained using a Molecular Devices OPTImax
Microplate Reader and the SoftMax® Pro 3.0 software. Data were
expressed on a scale where maximal proliferation in controls
(EGM2S+ at 72 h) was set to 100%.
2.6. Scratch assay
HUVEC migration was assessed using the IncuCyte ZOOM Scratch
assay (Essen Bioscience, Hertfordshire, UK) according tomanufacturer's
instructions. Brieﬂy, 3 × 104 HUVECs/well were seeded in 96-well cul-
ture plates and cultured for 18 h in EGM2S+ at 37 °C, 5% CO2. A scratch
was then made using the WoundMaker tool (Essen Bioscience). The
cells were washed twice with medium, and the medium was then re-
placed with EGM2S+, EGM2S−, CMS, CMS + Dex (50 nM) or CMD.
10-Fold concentrated CM were diluted 1:1 with EGM2S−. Plates were
then installed in the IncuCyte ZOOM system and images (10×magniﬁcation) of the wound were recorded in each well every hour
for 48 h. Scratch closure rate was evaluated with the IncuCyte software,
expressed as percentage of relative wound density (RWD) over a 30 h
period. RWD= 0 at time 0 and 100% when cell conﬂuence within the
wound area is equal to that outside the initial wound area, thus normal-
izing for changes in cell density due to proliferation or other non-
motogenic pharmacological effects. The area under the curve (AUC)
was calculated for each condition and the results are expressed as AUC
from RWD.
2.7. Tube-like structure (TLS) formation assay
The TLS assay was performed by seeding HUVECs or HAoECs onto
Matrigel™, as previously described [37]. Brieﬂy, HUVECs and HAoECs
(15 × 103 cells/well) were seeded in 96-well plates coated with
Matrigel™matrix (Corning, Flintshire, UK) in either EGM2S+, DMEM,
CMS or CMD. DMEM and 10-fold concentrated CM were diluted 1:4
with EGM2S+. This assay required a lower concentration of CM than
that used in other experiments (4:1 ratio EGM2S+:CM, giving a ﬁnal
concentration of 2× basal CM) as ECs failed to generate TLS networks
when EGM2S+ was used in 1:1 ratio with DMEM. Phase-contrast im-
ages (5× magniﬁcation) of the centre of each well were taken 3 h, 6 h
and 23 h post induction and TLS formation was evaluated using the An-
giogenesis Analyzer plug-in developed for the ImageJ software [33] by
Carpentier et al. [38]. The total length of tubes, number of junctions,
and number of segments were calculated from images taken when the
network reached stability (6 h post induction for HUVECs; 3 h post in-
duction for HAoECs).
2.8. Aortic ring assay
For the ex vivo aortic ring assay [39] C57BL/6 male mice aged 8–
12 weeks (Charles River Laboratories) were sacriﬁced by CO2 asphyxia-
tion at day 0 and the thoracic aortas were isolated and washed with
serum-free DMEM. Isolated aortaswere cleaned of connective tissue, di-
vided into 1–2mmrings and embedded in rat tail collagen type 1 (1mg/
ml, Sigma-Aldrich). Rings were then incubated (37 °C, 5% CO2) in
serum-free DMEM (control), CMS, CMS + Dex (50 nM) or CMD. 10-
fold concentrated CM were diluted 1:1 with serum-free DMEM. Media
were replaced after 3 and 7 days in culture. Phase-contrast microscopy
was used to count outgrowths on days 5, 7 and 10. Phase-contrast im-
ages (5× magniﬁcation) were taken at the corresponding time points.
Sprout lengths were measured on pictures obtained after 10 days post
treatment using ImageJ software [33]. Higher power images of formed
sprouts are displayed in Supplementary Fig. 6.
2.9. Statistical analyses
Data are presented asmean± standard deviation or as a Tukey's box
plot (Suppl. Fig. 2). Statistical analysis was performed using GraphPad
Prism 5.03 with a one-way analysis of variance (ANOVA) and Tukey's
multiple comparisons post-test, or with Mann-Whitney U test, as ap-
propriate. The applied test is indicated in the ﬁgure legends. A p b 0.05
was considered statistically signiﬁcant. Where applicable, results were
expressed as a relative number and the untreated condition was set as
1, 100 or 100% and other conditions were recalculated accordingly.
3. Results
3.1. Glucocorticoids modify secretion of angiogenic factors by
myoﬁbroblasts
In order to obtain a broader insight into the effects of GRmodulation
on colon cancer-derived myoﬁbroblasts, we performed a protein array
which detects over 500 different proteins from cell supernatants. Anal-
ysis of the protein array data (Fig. 1A) indicated that incubation with
Fig. 1.Glucocorticoids alter the secretion of proteins implicated in angiogenesis from culturedmyoﬁbroblasts. (A) CT5.3hTERT cells were treatedwith solvent or Dex (1 μM). After 48 h cell
supernatants were collected, 4-fold concentrated and subjected to Ray Bio® Biotin Label-based Human Antibody Array I. Relevant fragments of the array are displayed. The six dots
displayed on the left of the array act as a positive control (pos.ctrl.). (B) CT5.3hTERT cells were treated with solvent, Dex (1 μM), CpdA (10 μM), Hcrt (1 μM), Pred (1 μM), or RU
(2 μM) or co-treated with Dex (1 μM) and RU (2 μM) for 48 h. Cell supernatants were collected, 10-fold concentrated and subjected to Western blot analysis for the detection of uPA,
ANG and ANGPTL2. Protein bands representing ANGPTL2 belong to the same blot. Results are representative of three independent experiments. (A, B) Western blot and protein array
signals were quantiﬁed using ImageJ software [33]. (C, D, E) CT5.3hTERT cells were treated for 48 h with solvent, Dex (1 μM), CpdA (10 μM), Hcrt (1 μM), FA (1 μM), Pred (1 μM), RU
(2 μM) or co-treated with Dex (1 μM) and RU (2 μM). mRNA isolated from cells was subjected to RT-qPCR assaying uPA, ANG and ANGPTL2 mRNA levels. Results were normalized to
the respective geometric mean of GAPDH, PPIB and 36B4 reference genes' mRNA levels. Results are shown as the mean ± SD of three independent experiments and statistical analysis
was performed using a one-way analysis of variance (ANOVA) and Tukey's multiple comparisons post-test. ns: not signiﬁcant, *: p b 0.05, ***: p b 0.001.
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ogen activator (uPA) and angiopoietin-like protein-2 (ANGPTL2), but
increased expression of angiogenin (ANG) in supernatant from
CT5.3hTERT myoﬁbroblasts. The array also identiﬁed a number of fac-
tors present in the CM from myoﬁbroblasts that were not sensitive to
Dex treatment. Selected angiogenesis-related and inﬂammatory factors
are listed in the Supplementary Table 2.
Western blot analyses (Fig. 1B) and RT-qPCRs (Fig. 1C–E), were used
to verify the results obtained from the protein array and to possibly ex-
tend our ﬁndings to other GR ligands and modulators. Western blot
analysis of 10-fold concentrated cell supernatants conﬁrmed that Dex
(1 μM; 48 h) reduced protein levels of uPA, and ANGPTL2, whilstincreasing ANG protein levels (Fig. 1B). A similar regulation pattern
was seen with other glucocorticoids (Hcrt and Pred). In contrast, the
SEGRM CpdA (10 μM; 48 h) did not reduce uPA and ANGPTL2 protein
levels and did not upregulate ANG. RU (2 μM; 48 h) alone had no effect,
but blocked Dex-induced changes which suggests a GR-regulated
mechanism. RT-qPCR of mRNA isolated from CT5.3hTERT cells showed
that glucocorticoids seemed to reduce expression of uPA (Fig. 1C) and
ANGPTL2 (Fig. 1D), but this only achieved signiﬁcance for the effects
of Dex and Pred on ANGPTL2. The length of exposure to Dex matters
here, as Dex-induced reduction of uPA expression was found to be sig-
niﬁcant after a shorter (6 h) exposure (Supplementary Fig. 1). Consis-
tently, all glucocorticoids signiﬁcantly upregulated ANG (Fig. 1E). In
23Z. Drebert et al. / Vascular Pharmacology 89 (2017) 19–30contrast, to what is observed for protein, CpdA yielded different results
at the transcriptional level, following48h of treatment, and upregulated
the mRNA levels of uPA, ANGPTL2 and ANG. Treatment with RU had no
effect on ANG and ANGPTL2 mRNA levels, but dramatically increased
expression of uPA. Any effect of Dexwas lost or reduced in the presence
of RU (Fig. 1C–E).
3.2. Conditionedmedium fromdexamethasone-treatedmyoﬁbroblasts con-
tains decreased levels of prostanoids
Prostanoids are known to inﬂuence cell proliferation and migration.
Immunoassays (ELISAs) demonstrated that PGF2α, PGI2 (by assessing 6-
keto-PGF1α) and PGE2 were all present in conditioned medium from
solvent-treated myoﬁbroblasts (CMS) (Fig. 2). There was a pattern of
decreased levels of all three prostanoids in conditioned medium from
myoﬁbroblasts exposed to dexamethasone (CMD), which achieved sig-
niﬁcance for PGF2α (Fig. 2A) and PGI2 (Fig. 2B) but not for PGE2 (Fig. 2C).
Immunoassays (ELISA) demonstrated that PGF2α, PGI2 and PGE2
were also present in medium from HUVECs (Supplementary Fig. 2A–
C). Exposure to CMS (24 h) did not alter the concentration of these
prostanoids in HUVEC supernatants and this response was not altered
if the conditioned medium was derived from Dex-treated
myoﬁbroblasts (CMD). These prostanoids were also detected in
HUVEC lysates but their concentrations were not altered by 24 h expo-
sure to CMS or CMD (Supplementary Fig. 2D–F).
3.3. HUVEC proliferation is promoted by conditioned medium from
myoﬁbroblasts
The impact of conditionedmedium frommyoﬁbroblasts on the basic
endothelial character of HUVECs was assessed using an Ac-LDL uptake
assay. Results indicate Ac-LDL uptakewas not altered inHUVECs follow-
ing 24 h exposure to DMEM, CMS or CMD (Supplementary Fig. 3).
Prior to proliferation experiments, anMTT assay was performed and
demonstrated no negative effect on viability or metabolism from either
treatment (Fig. 3A). On the contrary, CMS andCMD treatment increased
the production of the MTT formazan product.
In order to investigate the impact ofmyoﬁbroblast CM on EC growth
we performed an SRB assay. In comparison with the control treatment
(EGM2S+) HUVEC proliferation was reduced by exposure to DMEM
(Fig. 3B). However, proliferation was increased compared with
EGM2S+ when the HUVECs were exposed to CMS after 48 and 72 h.
Use of CMD did not result in a signiﬁcant difference with the EGM2S+
control.
In the absence of FCS (Fig. 3C), both CMS and CMD induced a dra-
matic increase in HUVEC proliferation compared with EGM2S− control,
at 24 h and 72 h post treatment. Addition of Dex (50 nM) to CMSdid not
alter HUVEC proliferation.Fig. 2. Conditionedmedium fromdexamethasone-treatedmyoﬁbroblasts contains reduced leve
supernatants were collected, 10-fold concentrated and analyzed (ELISA) for (A) PGF2α, (B) P
independent experiments and statistical analysis was performed using a one-way analysis of va3.4. Conditionedmedium from solvent-treatedmyoﬁbroblasts causes an in-
crease in HUVEC migration which is lost with conditioned medium from
Dex-treated cells
One of the crucial events of angiogenesis includes EC migration into
perivascular stroma, due to the presence of pro-angiogenic factors. In
the scratch assay (Fig. 4, Supplementary Fig. 4), 30 h exposure to CMS
increased (by approximately 25% compared with EGMS−) the area
under the curve (AUC) (Fig. 3C), indicating accelerated wound healing.
This acceleration was not seen when cells were exposed to CMD (Fig.
4B, C). These data suggest, therefore, that CMS contains a factor(s)
that stimulate HUVECmigrationwhich is not present in CMD. Direct ad-
dition of Dex (50 nM) did not abolish the CMS-induced increase in
wound healing (Fig. 4B, C), indicating the lack of effects with CMD
was not due to residual Dex.3.5. Conditioned medium from myoﬁbroblasts does not inﬂuence tube-like
structure formation by HUVECs or HAoECs
The ability of ECs to form three-dimensional structures (tube-like
structures, TLS) represents cell differentiation belonging to a later
phase of angiogenesis (Supplementary Fig. 5). The ability of HUVECs
to form a net of TLS was mildly impaired after incubation with DMEM,
CMS or CMD diluted in a ratio of 1:4 with EGM2S+, as compared to un-
treated control (EGM2S+). This inhibition only achieved signiﬁcance for
total tubule length (Fig. 5A), but not for number of junctions (Fig. 5B) or
number of segments (Fig. 5C). Exposure to conditioned media had a
similar effect in HAoECs with neither CMS nor CMD signiﬁcantly alter-
ing total tubule length (Fig. 5D), number of junctions (Fig. 5E) or num-
ber of segments (Fig. 5F).3.6. Conditioned medium from myoﬁbroblasts alters gene expression in
HUVECS
In order to investigate whether the CM from myoﬁbroblasts affects
the expression of angiogenesis-related genes in HUVECs, we performed
RT-qPCR for VEGF, VEGFR1, VEGFR2 and IL-6. RT-qPCR was run on
mRNAobtained fromHUVECs exposed for 24h toDMEMor conditioned
medium, diluted in a 1:1 ratio with EGM2S+. Exposure to CM produced
an apparent reduction in VEGFmRNAexpression (Fig. 6A) that achieved
signiﬁcance (0.62-fold change) only for the comparison of CMSwith the
untreated (EGM2S+) control. CM had little effect on VEGFR1 (Fig. 6B) or
VEGFR2 (Fig. 6C) mRNA, with a small increase (1.63 fold change) in
VEGFR1 seen only when CMD-treated cells were compared with un-
treated (EGM2S+) controls. In contrast, exposure to CMS induced a
clear (2.16-fold) increase in IL-6 transcripts (Fig. 6D)whichwas not ob-
served when cells were exposed to CMD.ls of prostanoids. CT5.3hTERT cells were treatedwith solvent or Dex (1 μM). After 48 h cell
GI2 (by assessing 6-keto-PGF1α) and (C) PGE2 levels. Results are the mean ± SD of four
riance (ANOVA) and Tukey'smultiple comparisons post-test, ns: not signiﬁcant, *: p b 0.05.
Fig. 3.HUVEC proliferation is promoted by conditioned medium frommyoﬁbroblasts. (A) HUVECs were treated with EGM2S+ mixtures with DMEM, CMS or CMD in 1:1 ratio. After 24 h
cells were subjected toMTT assay and percentage cell viability was assessed. Obtained values were normalized to the values obtained from cells treated with DMEM and other conditions
were recalculated accordingly. (B) HUVECswere treatedwith either EGM2S+ (control) orwith EGM2S+mixtureswithDMEM, CMS or CMD in 1:1 ratio. After 24 h, 48 h and 72h cellswere
subjected to SRB assay andpercentage cell proliferationwas calculated. Obtained valueswere normalized to a control of untreated cells at 72h,which indicates theirmaximal proliferation.
(C) HUVECs were treated with either EGM2S+, EGM2S− or with EGM2S−mixtures with DMEM, CMS, CMD or CMS + Dex (50 nM) in 1:1 ratio with EGM2S−. Obtained values were
normalized to a control of cells treated with EGM2S+ at 72 h, which indicates their maximal proliferation. Results (A, B, C) are the mean ± SD of at least three independent
experiments and statistical analysis was performed using a one-way analysis of variance (ANOVA) and Tukey's multiple comparisons post-test. ns: not signiﬁcant, *: p b 0.05, **:
p b 0.01, ***: p b 0.001.
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Fig. 4.Acceleration ofHUVECmigration bymyoﬁbroblast conditionedmedium is lostwhen themyoﬁbroblasts are exposed to dexamethasone. (A, B, C)HUVECswere cultured in EGM2S+.
After 18 h awoundwas created in the conﬂuent cellmonolayer. Cellswerewashed and treatedwith either EGM2S+, EGM2S−, or EGM2S−mixtureswith CMS, CMDor CMS+Dex (50 nM)
in 1:1 ratio. (A, B) The wound healing process was examined with the IncuCyte ZOOM system, measuring percentage relative wound density (RWD) for each condition every hour. (C)
Area under curve (AUC) was calculated for each treatment and displayed in parallel. Results (A, B, C) are represented as the mean ± SD of four independent experiments and
statistical analysis was performed using a one-way analysis of variance (ANOVA) and Tukey's multiple comparisons post-test. ns: not signiﬁcant, ***: p b 0.001.
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tion from mouse aortic rings
The organ culture-aortic ring assay enabled investigation of the ef-
fects of myoﬁbroblast conditioned medium in a more complex model
of angiogenic tube formation, involving the presence of non-endothelial
cells (smooth muscle cells, ﬁbroblasts, pericytes, inﬂammatory cells) in
an intact arterial ring (rather than in 2 dimensional culture). Ex vivoout-
growth vessel formation in mouse aortic rings (Fig. 7) was increased by
exposure to CMS after 5 days (Fig. 7A), 7 days (Fig. 7B) and 10 days (Fig.
7C) of incubation, compared to untreated control (DMEM). This effect
was less pronounced using CMD and by addition of Dex (50 nM) to
CMS. In addition, the length of outgrowths (Supplementary Fig. 6)
was reduced by exposure to CMD or by addition of Dex (50 nM) to
CMS (Fig. 8).
4. Discussion
This investigation addressed the hypothesis that exposure of tumor-
derived myoﬁbroblasts to glucocorticoids would reduce secretion ofangiogenic factors and inhibit their ability to promote angiogenesis.
We showed that conditioned medium from colon cancer-derived
myoﬁbroblasts stimulated proliferation and migration of HUVECs. Se-
cretion of certain angiogenic factors was altered in conditionedmedium
fromDex-treatedmyoﬁbroblasts (CMD), and this was associatedwith a
reducedHUVECmigration, but did not affectHUVECproliferation. Expo-
sure to conditionedmedia only slightly altered expression of angiogenic
genes in HUVECs, and had no effect on tube-like structure formation in a
2-dimensional assay (with HUVECS and HAoECs). In contrast, in an ex
vivomodel (mouse aorta), conditioned media from myoﬁbroblasts in-
creased the number and length of vascular outgrowths. This effect was
impaired when myoﬁbroblasts had been exposed to Dex; most likely a
combined result of direct inhibition by residual steroid in the condi-
tioned medium together with Dex-driven reduction of certain factors
secreted by myoﬁbroblasts.
Angiogenesis is a complex,multi-step process regulated by a balance
between pro- and anti-angiogenic factors [1,3]. It can be modiﬁed at
various stages, including degradation of basement membrane and EC
shape change, invasion,migration and proliferation of ECs to form ami-
grating column, EC differentiation, formation of tight connections and
Fig. 5. Conditioned medium from myoﬁbroblasts does not affect tube-like structure formation by HUVECs or HAoECs. HUVECs (A, B, C) and HAoECs (D, E, F) were seeded on Matrigel-
coated wells and treated with either EGM2S+ or EGM2S+ mixtures with DMEM, CMS or CMD in 1:4 ratio. Phase-contrast images were taken at 6 h post induction for HUVECs and 3 h
post induction for HAoECs. The total tubule length (A, D), number of junctions (B, E) and number of segments (C, F) were assessed using Angiogenesis Analyzer plug-in for ImageJ
software [33,38]. Results are the mean ± SD of three independent experiments and statistical analysis was performed using a one-way analysis of variance (ANOVA) and Tukey's
multiple comparisons post-test, ns: not signiﬁcant, *: p b 0.05.
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pruning [40]. Stromal myoﬁbroblasts have the potential to regulate an-
giogenesis during tumor development. They are recruited by cancer
cells and act as potent promoters of tumor growth and invasion [10].
For example, breast cancer-associated ﬁbroblasts promote tumormicrovascularization, leading to enhanced tumor growth [12].
Myoﬁbroblast-mediated regulation of vessel formation in cancer could
be attributed to direct and/or indirect modulation of angiogenesis [8,
10]. We have previously shown the GC-sensitive and GR-regulated re-
lease of several pro-angiogenic factors (TNC, TGFβ and HGF/SF) by
Fig. 6. Inﬂuence of conditioned medium from myoﬁbroblasts on angiogenesis-related gene expression in HUVECs. (A, B, C, D) HUVECs were treated with either EGM2S+ or EGM2S+
mixtures with DMEM, CMS or CMD in 1:1 ratio. After 24 h, mRNA isolated from cells was subjected to RT-qPCR assaying (A) VEGF, (B) VEGFR1, (C) VEGFR2 and (D) IL-6 mRNA levels.
Obtained results were normalized to the respective geometric mean of GAPDH, PPIB and 36B4 reference genes' mRNA levels. Results are the mean ± SD of three independent
experiments and statistical analysis was performed using a one-way analysis of variance (ANOVA) and Tukey's multiple comparisons post-test. Ns: not signiﬁcant, *: p b 0.05, **:
p b 0.01, ***: p b 0.001.
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extends this work by showing that these cells secrete factors that pro-
mote survival, proliferation and migration of ECs. In culture conditions
devoid of serum, CM from colon cancer-derived myoﬁbroblasts could
compensate for the absence of FCS, thus maintaining HUVEC prolifera-
tion (Fig. 3C) and migration (Fig. 4A). A similar increase in HUVEC mi-
gration was demonstrated with CM collected from intestinal sub-
epithelial 18Co myoﬁbroblasts, an effect that was stimulated by pre-
treatment of the myoﬁbroblasts with prostaglandin (PG)E2[13].
Since myoﬁbroblastic CM regulated migration and proliferation of
ECs, it was reasonable to propose that it might also inﬂuence angiogen-
esis through direct interactionwith the endothelium. However, the fail-
ure of CM to stimulate TLS formation by HUVECs or HAoECs in a 2-
dimensional assay suggests that this was not the case (Fig. 5). Further-
more, a lack of effect on angiogenesis is consistent with the relatively
small impact of CM on expression of angiogenic factors in HUVECs
(Fig. 6). VEGF is a key promoter of angiogenesis, and acts through inter-
action with VEGFR2 [3,41]. VEGFR1, which has a 10-fold weaker kinase
activity than VEGFR2,may act as a VEGF-trap and, thus, suppress angio-
genesis [41,42]. IL-6 is a multifunctional pro-inﬂammatory cytokine
which has potent pro-angiogenic properties [43,44]. Interestingly, CM
from intestinal subepithelial 18Co myoﬁbroblasts were also ineffective
unless activated with PGE2, which increased VEGF expression in those
myoﬁbroblasts [13]. Similarly,mouse embryonicﬁbroblasts did not pro-
mote tube formation unless pre-treated with CM from gastric tumorcells, which increased expression of VEGF in the ﬁbroblasts [45]. These
ﬁndings suggest that CM obtained from colon-cancer myoﬁbroblasts
contain insufﬁcient levels of VEGF and, coupled with a lack of VEGF ac-
tivation in HUVECs treatedwith CM, could explain the inability of CM to
stimulate tube formation by isolated HUVECs and HAoECs.
GCs are exploited clinically, predominantly for their anti-inﬂamma-
tory properties, for the treatment of numerous disorders, including
asthma and rheumatoid arthritis [15]. They also serve as adjuvants in
tumor therapy [16]. However, the inﬂuence of GCs on the solid tumor
and its microenvironment is controversial and not fully understood
[46]. In prostate and breast cancer GC therapy has some beneﬁts,
whereas in gastro-intestinal cancer GC treatment has no effect and in
lung cancer may even be detrimental [47]. We have previously shown
that production and secretion of TNC, TGFβ and HGF/SF by
myoﬁbroblasts is reduced by GC treatment [25]. This is comparable
with the demonstration here that GCs reduce expression and secretion
of uPA and ANGPTL2, whilst upregulating ANG (Fig. 1). This response is
probably mediated via a GR-dependent mechanism, since Dex is rela-
tively GR selective and its effects were blocked by GR antagonism with
RU. The alterations in uPA, ANGPTL2 and ANG secretion were observed
with other GCs, namely Hcrt, FA and Pred. Although the non-steroidal
SEGRM CpdA [32] is able to transrepress the expression of several GR-
regulated genes in myoﬁbroblasts [25], it suppresses neither uPA nor
ANGPTL2 protein levels. As previously reported [25,32] CpdA is unable
to transactivate GC-inducible genes via a classic GRE-mediated
Fig. 7. Conditioned medium from myoﬁbroblasts promotes neovessel formation in mouse aortic rings embedded in collagen. (A, B, C) Explants were prepared from aortas isolated from
adultmale C57BL/6mice. After embedding in collagen, aortic ringswere cultured in serum-freeDMEM(control) or treatedwith CMS, CMDor CMS+Dex (50nM), in 1:1 ratiowith serum-
free DMEM. Vascular sprouts were quantiﬁed after 5 days (A1, A2), 7 days (B1, B2) and 10 days (C1, C2) in culture. Left panel histograms represent the mean ± SD of six independent
experiments. Results were analyzed using a one-way analysis of variance (ANOVA) and Tukey's multiple comparisons post-test. ns: not signiﬁcant, *: p b 0.05, **: p b 0.01, ***: p b 0.001.
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protein ormRNA level was not expected. These ﬁndings support a com-
monmechanism for the action of GCs and add to the evidence that CpdA
has different signaling properties than classic GCs [25]. The factors iden-
tiﬁed as affected by GCs have been linked to cancer progression and/or
angiogenesis. uPA regulates vascular remodeling [48] and its expressioncorrelates with tumor angiogenesis and tumor vessel invasion in gastric
and breast cancer [49,50]. ANG is named for its ability to stimulate ves-
sel growth, in normal and pathological states, including in tumors [51].
Angiopoietin-like proteins can stimulate vascular cells and inﬂuence
metabolism and tumor biology [52]. Thus it was logical to predict that
modulation of these factors by exposure of the myoﬁbroblasts to Dex
Fig. 8. Conditioned medium from myoﬁbroblasts increases outgrowth length in mouse
aortic rings embedded in collagen. Explants were prepared from aortas isolated from
adult male C57BL/6 mice. After embedding in collagen, aortic rings were treated with
CMS, CMD or CMS + Dex (50 nM), in a 1:1 ratio with serum-free DMEM. Images of
explants and vascular sprouts were captured after 10 days and measurement of
outgrowth length was performed using ImageJ software [33]. Results are the mean ±
SD of six independent experiments and were analyzed using a one-way analysis of
variance (ANOVA) and Tukey's multiple comparisons post-test. ns: not signiﬁcant, *:
p b 0.05, ***: p b 0.001.
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tors known to modulate inﬂammatory response and to promote cancer
progression [53,54], were also reduced by Dex treatment in
myoﬁbroblast conditionedmedium (Fig. 2). This corresponds with pre-
vious reports listing glucocorticoids as inhibitors of prostaglandin syn-
thesis [55].
The failure of CMD to alter the CMS-induced stimulation of HUVEC
proliferation (Fig. 2B, C) indicates that modulation of uPA, ANGPTL2,
ANG or prostaglandins does not inﬂuence growth of these cells. There
was no evidence that myoﬁbroblast conditioned media induce prosta-
glandin production by HUVECs. This contrasted with the dramatic re-
duction in HUVEC migration when CMD was compared with CMS (Fig.
3B, C). The fact that this effect was not replicated by direct addition of
Dex to CMS indicates that the reducedmigration is the result of changes
in the myoﬁbroblastic secretome. In support, some of the components
of CM that are suppressed by GC treatment can inﬂuence cell motility.
uPA release from TGFβ-stimulated endometrial stromal cells increases
migration of human microvascular ECs [56], whilst knock-down of the
ANGPTL2 gene impairs migration of endothelial colony forming cells
[57]. The same is true for HGF/SF and tenascin C, which we have previ-
ously shown to be downregulated by GCs [25]. HGF/SF has well-known
mitogenic and motogenic actions on ECs [58,59] and, thus, a reduction
in HGF/SF could explain impaired HUVEC migration by HUVECs.
Tenascin C promotes ECmigration by binding to annexin II on the target
cell surface, as well as by promoting phosphorylation of focal adhesion
kinase [60,61]. Thus, decreased levels of these proteins in CM from
Dex-treated myoﬁbroblasts are likely to explain the impaired
motogenic response seen in HUVECs. Prostaglandins, especially PGE2
and PGI2, are known pro-angiogenic factors that directly induce EC sur-
vival, migration and tube-formation by activating respective receptors
[54,62]. Therefore, insufﬁcient levels of these factors in CMD may have
also negatively inﬂuenced HUVEC migration.
It was notable that, in contrast to the 2-dimensional assay with
HUVECs and HAoECs (Fig. 5), CMS did increase the number and length
of vascular outgrowth formation in mouse aortic explants cultured ex
vivo (Figs. 7, 8). This is unlikely to be simply due to a functional differ-
ence between umbilical vein and aortic ECs as single cultures of HUVECs
and HAoECs responded in a similar way to CM in the TLS assay. Out-
growth formation in this assay is dependent on growth factor releasefromadventitial inﬂammatory cells [63]. Concomitant herewith, it is no-
table that the most dramatic change in transcript expression in HUVECs
treated with CMwas a 2-fold increase in IL-6 (Fig. 6D), a pro-inﬂamma-
tory cytokine that can inﬂuence angiogenesis. IL-6 and indeedmany in-
ﬂammatory proteins were not detected in the myoﬁbroblast
conditioned medium (Supplementary Table S2). It has been reported
that IL-6 stimulates angiogenesis directly leading to increased prolifera-
tion and migration of ECs [44], as well as endothelial progenitor cells
[43]. This suggests the presence of inﬂammation-stimulatingmolecules
in themyoﬁbroblastic secretome that are also sensitive to down-regula-
tion by GCs. These results suggest that CM from myoﬁbroblasts in-
creases angiogenesis indirectly by stimulation of growth factor release
by other (non-endothelial) cells in the vascular wall. The reduced effect
observed with CMD can be attributed to both Dex-driven reduction of
certain factors from myoﬁbroblastic secretome and residual Dex in the
medium, as addition of a comparable concentration of Dex to CMS had
a similar effect, but slightly less pronounced (Fig. 7). This is consistent
with the well-documented direct angiostatic properties of GCs [21–23,
39], including suppression of outgrowth formation in the aortic ring
assay [39].
In conclusion, this investigation has demonstrated that colon can-
cer-derived myoﬁbroblasts secrete pro-angiogenic factors and stimu-
late endothelial cell migration. This migration is inhibited by exposure
of the myoﬁbroblasts to GCs which alter the components of the
myoﬁbroblast secretome. A similarmodulation of angiogenesis appears
to be the result of indirect interaction of CM with non-endothelial vas-
cular cells, possibly through activation of vascular inﬂammatory path-
ways. This work suggests that treatment with GCs may reduce the
ability of cancer-derived myoﬁbroblasts to stimulate endothelial cell
migration and angiogenesis, through both direct and indirect effects
on the vascular wall.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.vph.2016.10.004.
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